Literature DB >> 32157225

CRISPR treatment inserted directly into the body for first time.

Heidi Ledford.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32157225     DOI： 10.1038/d41586-020-00655-8

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  24 in total

Review 1.  Active genetics comes alive: Exploring the broad applications of CRISPR-based selfish genetic elements (or gene-drives): Exploring the broad applications of CRISPR-based selfish genetic elements (or gene-drives).

Authors:  Valentino M Gantz; Ethan Bier
Journal:  Bioessays       Date:  2022-06-09       Impact factor: 4.653

Review 2.  Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications.

Authors:  Yue-Ying Huang; Xiao-Yu Zhang; Ping Zhu; Ling Ji
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

Review 3.  CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.

Authors:  Garima Sharma; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

Review 4.  3D engineering for optic neuropathy treatment.

Authors:  Wenjing Xuan; Aji Alex Moothedathu; Tuo Meng; David C Gibson; Jinhua Zheng; Qingguo Xu
Journal:  Drug Discov Today       Date:  2020-10-07       Impact factor: 7.851

5.  Application of CRISPR-Cas9 gene editing for congenital heart disease.

Authors:  Heeyoung Seok; Rui Deng; Douglas B Cowan; Da-Zhi Wang
Journal:  Clin Exp Pediatr       Date:  2021-03-02

6.  Spectrum of Disease Severity in Nonsyndromic Patients With Mutations in the CEP290 Gene: A Multicentric Longitudinal Study.

Authors:  Francesco Testa; Andrea Sodi; Sabrina Signorini; Valentina Di Iorio; Vittoria Murro; Raffaella Brunetti-Pierri; Enza Maria Valente; Marianthi Karali; Paolo Melillo; Sandro Banfi; Francesca Simonelli
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-07-01       Impact factor: 4.799

Review 7.  CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.

Authors:  Seyed Ahmad Rasoulinejad; Faezeh Maroufi
Journal:  Mol Biotechnol       Date:  2021-05-31       Impact factor: 2.695

8.  The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement.

Authors:  Graeme C Black; Panagiotis Sergouniotis; Andrea Sodi; Bart P Leroy; Caroline Van Cauwenbergh; Petra Liskova; Karen Grønskov; Artur Klett; Susanne Kohl; Gita Taurina; Marius Sukys; Lonneke Haer-Wigman; Katarzyna Nowomiejska; João Pedro Marques; Dorothée Leroux; Frans P M Cremers; Elfride De Baere; Hélène Dollfus
Journal:  Orphanet J Rare Dis       Date:  2021-03-20       Impact factor: 4.123

Review 9.  Pluripotent Stem Cell-Based Organoid Technologies for Developing Next-Generation Vision Restoration Therapies of Blindness.

Authors:  Ratnesh K Singh; Francois Binette; Magdalene Seiler; Simon M Petersen-Jones; Igor O Nasonkin
Journal:  J Ocul Pharmacol Ther       Date:  2020-10-14       Impact factor: 2.671

Review 10.  Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety.

Authors:  Lydia Teboul; Yann Herault; Sara Wells; Waseem Qasim; Guillaume Pavlovic
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.